Keith McCrae, MD, on Caplacizumab in Thrombotic Thrombocytopenic Purpura

2014 ASH Annual Meeting
Tweet this page

Keith McCrae, MD, of the Cleveland Clinic, offers his thoughts on abstract 229, “Caplacizumab, Anti-Vwf Nanobody Potentially Changing the Treatment Paradigm in Thrombotic Thrombocytopenic Purpura: Results of the TITAN Trial,” presented by Flora Peyvandi, MD.

Advertisement

Advertisement



Advertisement